RBBP4 promotes colon cancer malignant progression <i>via</i> regulating Wnt/β-catenin pathway

Li, Yandong; Lv, Zhen; Zhu, Weifang

doi:10.3748/wjg.v26.i35.5328

Cited by 21 publications

(25 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CCCTC-binding factor (CTCF) is a well-known regulator facilitating chromatin into topologically associated domains by enhancing cohesin-mediated loop formation [31], which is strongly associated with cancer initiation [32]. RBBP4 could promote the malignant progression of colon cancer through the Wnt/β-catenin pathway [33]. CDC23 regulates the tumour cell phenotype and is upregulated in papillary thyroid cancer [34].…”

Section: Discussionmentioning

confidence: 99%

Molecular Characterization and Clinical Relevance of m6A Regulators in Metastatic Prostate Cancer

Liu¹,

Li²,

He³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Prostate cancer is a leading malignancy in the male population globally. N6-methylation of adenosine (m6A) is the most prevalent mRNA modification and plays an essential role in various biological processes in vivo. However, the exact functions of m6A in metastatic prostate cancer are largely unknown. Here, we aimed to investigate the relative role of m6A regulators in metastatic prostate cancer.Methods: This study used RNA-seq and clinical data of metastatic prostate cancer to elucidate the association between N6 methylation and metastatic prostate cancer.Results: Based on 21 m6A regulators associated with prognosis, two molecular subtypes of metastatic prostate cancer were identified. Surprisingly, we observed that each subtype had unique prognostic characteristics. We then identified two subtypes of tumours based on 2330 m6A phenotype-associated genes, and one subtype was related to dismal prognosis. Finally, based on m6A-associated genes, we constructed a prognostic model to predict the outcomes of patients with metastatic prostate cancer. We found that this prognostic model was significantly correlated with biological functions such as DNA repair and mismatch repair, and patients with high m6A scores may be appropriate candidates for pharmacy therapy targeted for DNA repair, such as PARPi.Conclusion: This work illustrated the nonnegligible role of m6A modification in the prognosis of metastatic prostate cancer. Evaluating the m6A risk scores of individual tumours will guide more effective judgement of prognosis as well as treatments for metastatic prostate cancer in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular Characterization and Clinical Relevance of m6A Regulators in Metastatic Prostate Cancer

Liu¹,

Li²,

He³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The mixture was purified by column chromatography on silica gel eluted with dichloromethane: methanol (80 : 1) to get AD-PPD as white solid with 31.0 % yield. The structure of purified probe was verified by 1 H-NMR (500 MHz, CDCl 3 ) and 13 C-NMR (125 MHz, CDCl 3 ) at room temperature. Analytical data for the purified probe in the spectra of 1 H-NMR and 13 C-NMR (Figure S1 and Figure S2) were shown in Supporting Information.…”

Section: The Chemical Synthesis Of Ppd Probe (Ad-ppd)mentioning

confidence: 99%

“…The structure of purified probe was verified by 1 H-NMR (500 MHz, CDCl 3 ) and 13 C-NMR (125 MHz, CDCl 3 ) at room temperature. Analytical data for the purified probe in the spectra of 1 H-NMR and 13 C-NMR (Figure S1 and Figure S2) were shown in Supporting Information.…”

Section: The Chemical Synthesis Of Ppd Probe (Ad-ppd)mentioning

confidence: 99%

“…[11] Particularly, RBBP4 serves as a prognostic marker for poorer survival of patients with colorectal cancer. [12,13] Mechanically, RBBP4 contributes to the histone methyltransferase activity (H3K27me3) at subtelomeric domains of polycomb repressive complex 2 (PRC2), further leading to transcriptional repression of tumor suppressive genes. [14,15] Therefore, RBBP4 has been considered as an attractive therapeutic target against colorectal cancer currently, and small molecules selectively targeting RBBP4 have caused extensive attentions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Photoaffinity Labeling‐Based Chemoproteomic Strategy Reveals RBBP4 as a Cellular Target of Protopanaxadiol against Colorectal Cancer Cells

et al. 2022

View full text Add to dashboard Cite

Protopanaxadiol (PPD), a main ginseng metabolite, exerts powerful anticancer effects against multiple types of cancer; however, its cellular targets remain elusive. Here, we synthesized a cell-permeable PPD probe via introducing a bifunctional alkyne-containing diazirine photo-crosslinker and performed a photoaffinity labeling-based chemoproteomic study. We identified retinoblastoma binding protein 4 (RBBP4), a chromatin remodeling factor, as an essential cellular target of PPD in HCT116 colorectal cancer cells. PPD significantly decreased RBBP4-dependent trimethylation at lysine 27 of histone H3 (H3K27me3), a crucial epigenetic marker that correlates with histologic signs of colorectal cancer aggressiveness, and PPD inhibition of proliferation and migration of HCT116 cells was antagonized by RBBP4 RNA silencing. Collectively, our study highlights a previously undisclosed anti-colorectal cancer cellular target of the ginseng metabolite and advances the fundamental understanding of RBBP4 functions via a chemical biology strategy.

show abstract

“…CHAF1B protein expression in colon cancer positively correlates with Ki-67 expression, but proved not to have prognostic value [ 29 ]. RBBP4 protein expression is upregulated in colon cancer cell lines and clinical samples [ 53 , 54 ]. RBBP4 promotes tumorigenesis via the activation of the Wnt/β-catenin pathway [ 54 ], and there is a significant association between RBBP4 expression and vascular invasion, lymph node spread, hepatic metastasis, and reduced survival [ 53 ].…”

Section: Caf-1 Expression In Solid Tumoursmentioning

confidence: 99%

Challenging, Accurate and Feasible: CAF-1 as a Tumour Proliferation Marker of Diagnostic and Prognostic Value

Sykaras

Pergaris

Theocharis

2021

Cancers

View full text Add to dashboard Cite

The discovery of novel biomarkers of diagnostic, prognostic, and therapeutic value is a major challenge of current cancer research. The assessment of tumour cell proliferative capacity is pivotal for grading and clinical decision-making, highlighting the importance of proliferation markers as diagnostic and prognostic tools. Currently, the immunohistochemical analysis of Ki-67 expression levels is routinely used in clinical settings to assess tumour proliferation. Inasmuch as the function of Ki-67 is not fully understood and its evaluation lacks standardization, there is interest in chromatin regulator proteins as alternative proliferation markers of clinical value. Here, we review recent evidence demonstrating that chromatin assembly factor 1 (CAF-1), a histone chaperone selectively expressed in cycling cells, is a proliferation marker of clinical value. CAF-1 expression, when evaluated by immunocytochemistry in breast cancer cytology smears and immunohistochemistry in cancer biopsies from several tissues, strongly correlates with the expression of Ki-67 and other proliferation markers. Notably, CAF-1 expression is upregulated in almost all cancers, and CAF-1 overexpression is significantly associated, in most cancer types, with high histological tumour grade, advanced stage, recurrence, metastasis, and decreased patient survival. These findings suggest that CAF-1 is a robust, reproducible, and feasible proliferation marker of prognostic importance. CAF-1 may represent an attractive alternative or complementary to Ki-67 for cancer stratification and clinical guidance.

show abstract

RBBP4 promotes colon cancer malignant progression via regulating Wnt/β-catenin pathway

Cited by 21 publications

References 42 publications

Molecular Characterization and Clinical Relevance of m6A Regulators in Metastatic Prostate Cancer

Molecular Characterization and Clinical Relevance of m6A Regulators in Metastatic Prostate Cancer

Photoaffinity Labeling‐Based Chemoproteomic Strategy Reveals RBBP4 as a Cellular Target of Protopanaxadiol against Colorectal Cancer Cells

Challenging, Accurate and Feasible: CAF-1 as a Tumour Proliferation Marker of Diagnostic and Prognostic Value

Contact Info

Product

Resources

About